236 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (1752)
- Addiction (19)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- Cancer
(564)
- Bladder Cancer (13)
- Brain Cancer (12)
- Breast Cancer (60)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (64)
- Liver Cancer (4)
- Lung Cancer (57)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (25)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- (-) Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (165)
- Nutrition (5)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (103)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (48)
- Urology (4)
- Vascular Conditions (10)
Displaying 1 - 20 of 20
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Reilly Kayser, MD
Status: Closed
The Center for OCD Research at Columbia University Irving Medical Center is seeking individuals with obsessive-compulsive disorder (OCD) to participate in a research study, at no cost to you. This study is investigating the medicinal effects of nabilone for OCD symptoms. Nabilone is a synthetic form of tetrahydrocannabinol (THC), which is one of the active…
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This study will develop a data registry of patients diagnosed with uveal melanoma (UM). This registry will provide data that will be used to support the development of novel therapies for this disease. In this study, we are focused on trying to better understand how uveal melanoma behaves and how it is treated at different medical centers around the country.
Condition: Blood Disorders / Sickle Cell Disease
Investigator: Monica Bhatia, MD
Status: Closed
The purpose of this study is to find out if the study medicine called EDIT-301 will help in the treatment of Severe Sickle Cell Disease (SCD) and how safe it is to be used in people. EDIT-301 (study medicine) is a new investigational therapy which uses the patient's own stem cells, modifies them by CRISPR technology, and infuses them back to the…
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Amy Rapp, PhD
Status: Closed
The goal of the project is to identify differences in learning in obsessive-compulsive disorder (OCD) by measuring the activity of the brain while participants complete computer tasks. Eligible participants will be asked questions about their medical and psychiatric history and perform tasks on a computer while an electroencephalogram (EEG) is recorded.…
Condition: Blood Disorders / Sickle Cell Disease
Investigator: Andrew Eisenberger, MD
Status: Closed
The purpose of this study is to learn about whether the study drug (PF-07209326) is safe and effective in people with sickle cell disease and learn about what the right dose is. We will look at drug levels in the blood, see how fast drug levels rise and fall, and what effects the drug has, all of which are known as the pharmacokinetics (PK) and…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
You are invited to join voluntarily in a clinical research study to find out if the drug LXS196 alone or in combination with HDM201 is safe and has beneficial effects in people who have metastatic uveal melanoma. The purpose of this study is to determine the highest dose of LXS196 that can be given safely without unacceptable side effects as a single drug…
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Reilly Kayser, MD
Status: Closed
The Center for OCD and Related Disorders at New York State Psychiatric Institute/Columbia University Medical Center is seeking individuals aged 18+ with obsessive-compulsive disorder (OCD) to participate in a survey regarding their experiences with marijuana/cannabis. We hope this study will lead to increased understanding of how these substances affect…
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This research study is being done to see if the study drug, IMCgp100, works and is safe as treatment for subjects with uveal melanoma who also test positive for HLA-A*0201. In this study IMCgp100 will be compared to three standard treatments: dacarbazine (a chemotherapy drug), ipilimumab (an immunotherapy drug), or pembrolizumab (an immunotherapy drug).…
Condition: Blood Disorders / Sickle Cell Disease
Investigator: Monica Bhatia, MD
Status: Closed
This study is being done to see if giving your child a lower dose of chemotherapy (drug therapy), than has been used historically in bone marrow transplant, to kill his/her own diseased cells before he/she receives a bone marrow transplant, will possibly result in the permanent control of your child's sickle cell disease. Patients will receive busulfan…
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the medication Selumetinib will have on you and your uveal melanoma. Selumetinib is a medication that blocks (or turns off) MEK, a protein activated in some uveal melanoma cells. Selumetinib is a MEK inhibitor. Blocking MEK may stop your cancer from growing.
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Helen Simpson, MD, PhD
Status: Closed
Eligible participants will be asked questions about their symptoms, complete questionnaires, and receive sessions of Cognitive-Behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP) accompanied by the use of a mobile app. The purpose of this study is to assess whether the mobile app may be effective in improving symptoms of OCD.
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Pablo Goldberg, M.D.
Status: Closed
The purpose of this study is to assess the effects of a single infusion of ketamine for adolescents and young adults with obsessive-compulsive disorder (OCD). Ketamine is a FDA-approved anesthetic medication that can possibly cause a rapid decrease in OCD symptoms. To be eligible to participate, patients need to have already tried at least one SRI…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
This is a Phase I study of a weekly intra-patient escalation dose regimen with IMCgp100 in patients with metastatic uveal melanoma (mUM). To help decide whether or not patients can take part in a research study looking at a new form of treatment for advanced uveal melanoma, their blood need to first be tested to determine their Human Leukocyte Antigen (HLA…
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Helen Simpson, MD, PhD
Status: Closed
The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on…
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Helen Simpson, MD, PhD
Status: Closed
This study is investigating how the brains of people with OCD may change with treatment. The study uses Magnetic Resonance Imaging (MRI) to scan the brain, and the treatment used is a form of Cognitive-Behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP). Participants will undergo a scan, which lasts for approximately 2 hours and takes…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the treatment part of the study is to find out what effects drug crizotinib has, good and/or bad on people with "high risk" uveal melanoma after surgery or radiation for the eye. It is thought that giving crizotinib to patients with "high risk" uveal melanoma can lower the chance the cancer will come back. Uveal melanoma…
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Yagna Pathak, PhD
Status: Closed
The study aims to assess the impact of repetitive transcranial magnetic stimulation (rTMS) on brain imaging and neurophysiological measures in patients with Obsessive-Compulsive Disorder (OCD).
Condition: Psychiatric Disorders / Obsessive Compulsive Disorder (OCD)
Investigator: Helen Simpson, MD, PhD
Status: Closed
The Center for OCD and Related Disorders is currently conducting a study in treating Obsessive-compulsive Disorder (OCD), which is a severe illness characterized by distressing intrusive thoughts, images, or impulses about a variety of themes (e.g., fears of contamination or harm) and repetitive behaviors such as excessive washing or checking. The study is…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is evaluate the benefits and safety of using the combination of drugs, AEB071 and BYL719 to treat patients with an advanced form of uveal melanoma. The study will have two parts. The first part twill test different dose levels of each drug.Once the highest safe dose level is found, another group of patients will be treated at that…
Condition: Blood Disorders / Sickle Cell Disease
Investigator: Nancy Green, MD
Status: Closed
The purpose of this research is to learn how to help parent youth pairs work together to help youth with sickle cell disease take hydroxyurea every day as a daily habit. This study is for children and teens ages 10-18 with Sickle Cell Anemia taking hydroxyurea, and their parents (or guardians). Many children and teens do not use hydroxyurea every day. Daily…